Pakistan has officially placed an order to procure the single-dose Coronavirus vaccine developed by the Chinese pharmaceutical company, CanSinoBIO, read a statement by the Ministry of Health.
According to the official statement, the first batch of CanSinoBIO’s COVID-19 vaccine consisting of 60,000 doses will reach Pakistan within a week.
ALSO READ
Indian Police Takes PIA’s ‘Spy Balloon’ Into Custody
Known as Ad5-nCoV, CanSinoBIO has developed the vaccine in collaboration with the Beijing Institute of Biotechnology and has tested it in large-scale phase-III clinical trials that were held in five countries, including Pakistan, in which more than 40,000 volunteers participated.
Results of trials have confirmed that the CanSinoBIO vaccine is 65% effective at preventing symptomatic cases and 91% effective at preventing severe infection.
As for the Pakistani subset, the vaccine offers 75% protection against symptomatic cases and 100% protection against severe infection.
ALSO READ
PDMA Issues Warnings for Land Slides Across KP
Moreover, no serious safety concerns and side-effects of the CanSinoBIO vaccine were reported during the multination clinical trials.
Last month, the Drug Regulatory Authority of Pakistan (DRAP) had granted Emergency Use Authorization (EUA) to CanSinoBIO’s COVID-19 vaccine.
